Importantly, even heterozygous carriers of GBA1 mutations—who typically do not manifest GD—have elevated risk for PD and DLB, which indicates that partial GCase deficiency (or dysfunction) in the brain is sufficient to modify risk of synucleinopathy [11]. The gene discussed is GBA1; the disease is synucleinopathy.